A FTO variant and risk of acute coronary syndrome
Jaroslav A. Hubáček(Institute of Clinical and Experimental Medicine), Jan Piťha(Centre of Civil Engineering (Czechia)), R. Poledne(Institute of Clinical and Experimental Medicine), Věra Lánská(Institute of Clinical and Experimental Medicine), Josef Veselka(University Hospital Kralovske Vinohrady), Michal Aschermann(University of South Bohemia in České Budějovice), M Gebauerová(Institute of Clinical and Experimental Medicine), Dana Dlouhá(Centre of Civil Engineering (Czechia)), Alexandra Pilipčincová(Institute of Clinical and Experimental Medicine), Jana Matoušková(General University Hospital in Prague), Martin Pěnička, Hana Skalická(University of Iowa), Hana Hrabáková(University Hospital Kralovske Vinohrady), Vladimír Staněk(Institute of Clinical and Experimental Medicine), Věra Adámková(Institute of Clinical and Experimental Medicine), Andreas Krüger(Na Homolce Hospital), Petr Hájek(University Hospital in Motol)
Cited by 65
Related Papers
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
|The Lancet|2014|709
Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study
|European Heart Journal - Cardiovascular Imaging|2017|348
Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study
|European Heart Journal - Cardiovascular Imaging|2018|336